Literature DB >> 3540888

Pyogenic arthritis in infants and children: a review of 95 cases.

C J Welkon, S S Long, M C Fisher, P D Alburger.   

Abstract

The clinical and laboratory findings of 95 children with pyogenic arthritis were reviewed to assess etiologic agents, diagnostic tools and results of therapy. Despite obtaining specimens from multiple sites for culture and using antigen detection tests only 64% of patients had an etiologic agent determined. Haemophilus influenzae type b was the most common causative agent identified and 82% of such cases occurred in children between 6 and 24 months of age. Infection due to Staphylococcus aureus was not confined to any age group. Results of laboratory tests which measure inflammatory response were not always abnormal. Platelet count and sedimentation rate frequently rose as clinical improvement occurred. Roentgenograms and radionuclide studies were of little benefit. Therapy included immediate decompression of the joint space, articular rest and use of antibiotics delivered parenterally. Ninety percent of 70 patients who were followed for 1 month to 5 years (mean, 15.5 months) were cured. Eight children had clinically significant sequelae which affected length of extremity, stability of articulations and range of movement. Development of sequelae was significantly associated with infection at age less than 6 months, delay of 4 or more days in institution of medical or surgery treatment, infection due to S. aureus and most strikingly the involvement of the hip or shoulder with concomitant presence of osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3540888     DOI: 10.1097/00006454-198611000-00014

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  16 in total

1.  Tampon sampling for diagnosis of bacterial vaginosis: a potentially useful way to detect genital infections?

Authors:  D Wilkinson; N Ndovela; A Kharsany; C Connolly; A W Sturm
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Use of the isolator 1.5 microbial tube for culture of synovial fluid from patients with septic arthritis.

Authors:  P Yagupsky; J Press
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

3.  The use of antibiotic therapy as an adjunct in treatment of bone and joint infections.

Authors: 
Journal:  Can J Infect Dis       Date:  1994-01

Review 4.  A practical guide to the diagnosis and management of bone and joint infections.

Authors:  J T Mader; D Mohan; J Calhoun
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

5.  Nationwide survey of pediatric septic arthritis in the United States.

Authors:  Yusuke Okubo; Kotaro Nochioka; Testa Marcia
Journal:  J Orthop       Date:  2017-06-23

6.  High prevalence of Kingella kingae in joint fluid from children with septic arthritis revealed by the BACTEC blood culture system.

Authors:  P Yagupsky; R Dagan; C W Howard; M Einhorn; I Kassis; A Simu
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

Review 7.  US Evaluation of Juvenile Idiopathic Arthritis and Osteoarticular Infection.

Authors:  Jie C Nguyen; Kenneth S Lee; Mahesh M Thapa; Humberto G Rosas
Journal:  Radiographics       Date:  2017 Jul-Aug       Impact factor: 5.333

8.  Hip Synovial Fluid Cell Counts in Children From a Lyme Disease Endemic Area.

Authors:  Arianna H Dart; Kenneth A Michelson; Paul L Aronson; Aris C Garro; Thomas J Lee; Kimberly M Glerum; Peter A Nigrovic; Mininder S Kocher; Richard G Bachur; Lise E Nigrovic
Journal:  Pediatrics       Date:  2018-04-18       Impact factor: 7.124

9.  Metaphyseal osteomyelitis in children: how often does MRI-documented joint effusion or epiphyseal extension of edema indicate coexisting septic arthritis?

Authors:  Erica K Schallert; J Herman Kan; Johanna Monsalve; Wei Zhang; George S Bisset; Scott Rosenfeld
Journal:  Pediatr Radiol       Date:  2015-02-20

Review 10.  Management of septic arthritis.

Authors:  Avinash K Shetty; Abraham Gedalia
Journal:  Indian J Pediatr       Date:  2004-09       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.